Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

Kidney Transplant Immunosuppression Clinical Trial

Official title:
An Extension Protocol for Subjects Previously Enrolled in the "Use of Donor Derived-cell Free DNA (AlloSure) and Gene Expression Profiling (AlloMap Kidney) to Facilitate Belatacept Monotherapy in Kidney Transplant Patients"

Status Not yet recruiting

Clinical Trial Summary

The purpose of the study is to provide immunosuppression weaning and/or monitoring for an additional 12-months to evaluate the safety and efficacy of belatacept monotherapy in patients previously enrolled in the clinical trial: "Use of donor derived-cell free DNA (AlloSure) and gene expression profiling (AlloMap Kidney) to facilitate Belatacept monotherapy in kidney transplant patients."

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Kidney Transplant Immunosuppression

Clinical Trial Details

NCT number	NCT06336863
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact	David Wojciechowski, DO
Phone	214-645-7846
Email	David.Wojciechowski@UTSouthwestern.edu
Status	Not yet recruiting
Phase	N/A
Start date	June 2024
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04786067` - Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression	Phase 4
Recruiting	`NCT06114953` - Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients	Phase 4
Terminated	`NCT01424345` - The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient	Phase 4